Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Objective Response to Tarloxotinib Administered Intravenously to Patients With Non Small Cell Lung Cancer That Harbors Either EGFR Exon 20 Insertion or a HER2-Activating Mutation

Trial Profile

A Phase 2 Study to Evaluate the Objective Response to Tarloxotinib Administered Intravenously to Patients With Non Small Cell Lung Cancer That Harbors Either EGFR Exon 20 Insertion or a HER2-Activating Mutation

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tarloxotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms RAIN
  • Sponsors Rain Therapeutics
  • Most Recent Events

    • 19 Mar 2019 According to a Rain Therapeutics media release, the company announced the dosing of the first patient in this study. The start of the Phase 2 trial comes within 10 months of the Company announcing its Series A financing.
    • 01 Mar 2019 Status changed from not yet recruiting to recruiting.
    • 14 Jan 2019 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top